AI Article Synopsis
- This review focuses on treatment options for oropharyngeal squamous cell carcinoma (OPSCC), highlighting its molecular mechanisms within head and neck cancers.
- Treatment approaches can either be radical (aimed at curing the disease) or palliative (focused on disease control and relieving symptoms).
- Key findings show that radiotherapy is the primary treatment choice for OPSCC in many countries, while surgical options are limited; molecular therapies are still mainly in preclinical stages, with several drugs currently undergoing clinical testing.
Article Abstract
Objectives: In this review, we discuss oropharyngeal squamous cell carcinoma (OPSCC) treatment options with a focus on the molecular mechanisms of OPSCC in head and neck squamous cell carcinoma (HNSCC) and head and neck cancers (HNCs). Treatment can be radical intent (aim for cure) or palliative intent (aim for disease control and symptom management). OPSCC is a prominent subset of HNSCCs in Australia and the Western World.
Method: We looked at the current conventional treatment options with an overview of recent advances and future endeavours.
Key Findings: We identified that radiotherapy is the primary management for OPSCC in most countries, including the USA, UK, NZ, and Australia. In contrast, surgery is only considered for superficial OPSCC or neck surgery. If surgery is incomplete, then definitive management still requires radiotherapy.
Conclusion: Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpp/rgae107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!